THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that an article has been published in the July 1, 2007 issue of Oncology Reports indicating a potential for a new approach to the treatment of breast cancer using Proellex. The article reviews the findings from a study conducted in an accepted in vivo rat model of breast cancer. The study was conducted in collaboration with scientists from the University of Illinois at Chicago College of Medicine and IIT Research Institute.
